-
Person-centric clinical trials: defining the N-of-1 clinical trial utilizing a practice-based translational network
Frederick A Curro, Dennis A Robbins, Frederick Naftolin, Ashley C Grill, Don Vena & Louis Terracio
Clinical Trail Perspective: Clinical Investigation
-
Person-centric clinical trials: defining the N-of-1 clinical trial utilizing a practice-based translational network
Frederick A Curro, Dennis A Robbins, Frederick Naftolin, Ashley C Grill, Don Vena & Louis Terracio
Clinical Trail Perspective: Clinical Investigation
-
Person-centric clinical trials: defining the N-of-1 clinical trial utilizing a practice-based translational network
Frederick A Curro, Dennis A Robbins, Frederick Naftolin, Ashley C Grill, Don Vena & Louis Terracio
Clinical Trail Perspective: Clinical Investigation
-
Person-centric clinical trials: defining the N-of-1 clinical trial utilizing a practice-based translational network
Frederick A Curro, Dennis A Robbins, Frederick Naftolin, Ashley C Grill, Don Vena & Louis Terracio
Clinical Trail Perspective: Clinical Investigation
-
Person-centric clinical trials: defining the N-of-1 clinical trial utilizing a practice-based translational network
Frederick A Curro, Dennis A Robbins, Frederick Naftolin, Ashley C Grill, Don Vena & Louis Terracio
Clinical Trail Perspective: Clinical Investigation
-
Person-centric clinical trials: defining the N-of-1 clinical trial utilizing a practice-based translational network
Frederick A Curro, Dennis A Robbins, Frederick Naftolin, Ashley C Grill, Don Vena & Louis Terracio
Clinical Trail Perspective: Clinical Investigation
-
Person-centric clinical trials: defining the N-of-1 clinical trial utilizing a practice-based translational network
Frederick A Curro, Dennis A Robbins, Frederick Naftolin, Ashley C Grill, Don Vena & Louis Terracio
Clinical Trail Perspective: Clinical Investigation
-
Person-centric clinical trials: defining the N-of-1 clinical trial utilizing a practice-based translational network
Frederick A Curro, Dennis A Robbins, Frederick Naftolin, Ashley C Grill, Don Vena & Louis Terracio
Clinical Trail Perspective: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
OnabotulinumtoxinA for the treatment of overactive bladder
Altaf Mangera & Christopher R Chapple
Review: Clinical Trail Outcomes: Clinical Investigation
-
OnabotulinumtoxinA for the treatment of overactive bladder
Altaf Mangera & Christopher R Chapple
Review: Clinical Trail Outcomes: Clinical Investigation
-
OnabotulinumtoxinA for the treatment of overactive bladder
Altaf Mangera & Christopher R Chapple
Review: Clinical Trail Outcomes: Clinical Investigation
-
OnabotulinumtoxinA for the treatment of overactive bladder
Altaf Mangera & Christopher R Chapple
Review: Clinical Trail Outcomes: Clinical Investigation
-
OnabotulinumtoxinA for the treatment of overactive bladder
Altaf Mangera & Christopher R Chapple
Review: Clinical Trail Outcomes: Clinical Investigation
-
OnabotulinumtoxinA for the treatment of overactive bladder
Altaf Mangera & Christopher R Chapple
Review: Clinical Trail Outcomes: Clinical Investigation
-
OnabotulinumtoxinA for the treatment of overactive bladder
Altaf Mangera & Christopher R Chapple
Review: Clinical Trail Outcomes: Clinical Investigation
-
OnabotulinumtoxinA for the treatment of overactive bladder
Altaf Mangera & Christopher R Chapple
Review: Clinical Trail Outcomes: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
South East Scotland Cancer Research Network: an opportunity to expand
Vivienne Wilson
Research Update: Clinical Investigation
-
Defining efficacy in meningococcal vaccine trials
Paul B Keiser, Christopher J Gill
Review: Clinical Trail Outcomes: Clinical Investigation
-
Defining efficacy in meningococcal vaccine trials
Paul B Keiser, Christopher J Gill
Review: Clinical Trail Outcomes: Clinical Investigation
-
Defining efficacy in meningococcal vaccine trials
Paul B Keiser, Christopher J Gill
Review: Clinical Trail Outcomes: Clinical Investigation
-
Defining efficacy in meningococcal vaccine trials
Paul B Keiser, Christopher J Gill
Review: Clinical Trail Outcomes: Clinical Investigation
-
Defining efficacy in meningococcal vaccine trials
Paul B Keiser, Christopher J Gill
Review: Clinical Trail Outcomes: Clinical Investigation
-
Defining efficacy in meningococcal vaccine trials
Paul B Keiser, Christopher J Gill
Review: Clinical Trail Outcomes: Clinical Investigation
-
Defining efficacy in meningococcal vaccine trials
Paul B Keiser, Christopher J Gill
Review: Clinical Trail Outcomes: Clinical Investigation
-
Defining efficacy in meningococcal vaccine trials
Paul B Keiser, Christopher J Gill
Review: Clinical Trail Outcomes: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation